LifeSci Biotechnology Clinical Trials Index

Bloomberg: LSCIBC | Clinical-Stage Biotech

LSCIBP LSCIBC

Overview

LSCIBC
129 Components
$1.6B Median Mkt Cap
(as of 6/30/2026)
Equal Weighting
Semi-Annual Reconstitution

LSCIBC Index Performance

Past performance is not indicative of future results. One cannot invest directly in an index. Source: LifeSci Index Partners / Indxx, Inc.

What Is LSCIBC?

The LifeSci Biotechnology Clinical Trials Index tracks U.S.-listed pure biotechnology companies whose lead drug candidate is currently in Phase 1, 2, or 3 human clinical trials. With 129 components at equal weight, LSCIBC captures the high-growth, high-innovation segment of the biotech pipeline.

When to Use LSCIBC

LSCIBC is designed for investors seeking exposure to clinical-stage biotechnology — companies at the frontier of drug development with significant upside potential from trial data readouts, regulatory milestones, and M&A activity.

Invest via ETF

The Virtus Biotech Clinical Trials ETF (ticker BBC) provides direct access to the LSCIBC index. Explore fund details, holdings, and performance at Virtus.

Visit Virtus (BBC) →